tetano
Editor, Senior Moderator
J Virol. 2015 Dec 16. pii: JVI.02723-15. [Epub ahead of print]
[h=1]A single mutation at PB1 residue 319 dramatically increases the safety of PR8 LAIV in a murine model without compromising vaccine efficacy.[/h] Cox A[SUP]1[/SUP], Dewhurst S[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The live attenuated influenza vaccine (LAIV) is preferentially recommended for use in most children yet remains unsafe for the most at risk groups. Here we have improved the safety of a mouse adapted live attenuated influenza vaccine containing the same attenuating amino acid mutations as human LAIV, by adding an additional mutation at PB1 residue 319. This results in a vaccine with a 20 fold decrease in protective efficacy and a 10,000-fold increase in safety.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26676793 [PubMed - as supplied by publisher]
[h=1]A single mutation at PB1 residue 319 dramatically increases the safety of PR8 LAIV in a murine model without compromising vaccine efficacy.[/h] Cox A[SUP]1[/SUP], Dewhurst S[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The live attenuated influenza vaccine (LAIV) is preferentially recommended for use in most children yet remains unsafe for the most at risk groups. Here we have improved the safety of a mouse adapted live attenuated influenza vaccine containing the same attenuating amino acid mutations as human LAIV, by adding an additional mutation at PB1 residue 319. This results in a vaccine with a 20 fold decrease in protective efficacy and a 10,000-fold increase in safety.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26676793 [PubMed - as supplied by publisher]